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c-MYC and the SWI/SNF chromatin remodeling complex act as master
regulators of transcription, and play a key role in human cancer. Although
they are known to interact, the molecular details of their interaction are
lacking. We have determined the structure of the RPT1 region of the INI1/
hSNF5/BAF47/SMARCB1 subunit of the SWI/SNF complex that acts as
a c-MYC-binding domain, and have localized the interaction regions on
both INI1 and on the c-MYC:MAX heterodimer. c-MYC interacts with a
highly conserved groove on INI1, while INI1 binds to the c-MYC helix-
loop-helix region. The binding site overlaps with the c-MYC DNA-binding
region, and we show that binding of INI1 and E-box DNA to c-MYC:
MAX are mutually exclusive.
Introduction
The transcription factor c-MYC (hereafter MYC) acts
as a master regulator of genes involved in cell growth,
differentiation, metabolism, and apoptosis. Deregulated
expression of MYC occurs in the majority of human
cancers, playing a pivotal role in tumorigenesis and
cancer progression [1,2]. In mouse models, inactivation
of MYC dramatically halts tumor cell growth and pro-
liferation, without invoking tumor escape pathways
[1,2], making targeting MYC an attractive approach for
anticancer therapy [3]. MYC is also an emerging target
in other areas of human diseases, such as inflammation
and heart disease [4,5]. As MYC dramatically increases
the efficiency of somatic cell reprogramming, modulat-
ing MYC functions is also important in regenerative
medicine [6]. Although MYC physiology and pathology
have been extensively studied, we still do not know how
MYC works at the molecular level, which is a key to be
able to target it pharmacologically. MYC coordinates
Abbreviations
BAF, BRG1- or HBRM-associated factors; c-MYC, avian myelocytomatosis virus oncogene cellular homolog; HSQC, heteronuclear single
quantum coherence; INI1, integrase interactor 1; MAX, MYC-associated factor X; MIZ1, MYC-interacting zinc finger protein-1; PPI, protein–
protein interaction; SMARCB1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1; SWI/
SNF, SWItch/sucrose nonfermentable.
4165The FEBS Journal 285 (2018) 4165–4180 ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
the expression of a large, extremely diverse set of genes
in a highly context-dependent manner. MYC operates
within a network of protein–protein interactions (PPIs),
crucial for both directing MYC to specific genomic sites
and for modulating gene expression [7,8]. However, our
knowledge of these interactions is limited.
Several studies have shown that the SWI/SNF chro-
matin remodeling complex is part of the MYC interac-
tome [9–12]. This multiprotein complex [13] uses ATP
to alter chromatin structure by repositioning nucleo-
somes [13] and plays a key role in regulating gene
expression during cell differentiation. Mutations that
inactivate SWI/SNF subunits are found in around 20%
of human cancers [14]. Its role in cancer is complex as it
has reported that depending on the type of the tumor
the SWI/SNF complex can either inhibit tumor progres-
sion, or be required for cancer cell growth. Targeting
the SWI/SNF complex is, thus, paradoxically emerging
as a potential strategy for anticancer therapy [15].
The interplay between MYC and the SWI/SNF chro-
matin remodeling complex seems to be multifaceted and
very much context- and gene dependent [16–20].
The INI1 (syn hSNF5, BAF47, SMARCB1) subunit
[10,21,22] has been shown to play a major role in the
interaction of the SWI/SNF complex with MYC. This
subunit has also been implicated in the recruitment of
other transcription factors [23], other chromatin-
associated proteins and a number of viral proteins,
such as HIV integrase [24] and EPV EBNA2 [25].
INI1 was the first subunit of this complex identified to
be mutated in cancer. Nonsense mutations and dele-
tions that abolish INI1 expression are present in rhab-
doid tumors, the most common malignant CNS
tumors of children below 6 months of age. Analysis of
the genomes of rhabdoid tumors shows very few other
mutational events indicating that epigenetic dysregula-
tion is the central mechanism of oncogenesis [26].
In rhabdoid tumor-derived cells reintroduction of
INI1 appears to suppress MYC functions. In other
cancer cell lines, it has been shown instead that INI1
contributes to MYC transcriptional activity [21], and
that overexpression of the region of INI1 that binds to
MYC blocks MYC transcriptional activation [27].
We set out to determine how these two important tran-
scription regulators interact at the molecular level and have
revealed a complex network of competing interactions.
Results
Structure determination of INI1/hSNF5 RPT1
INI1 is a modular protein consisting of an N-terminal
winged-helix domain [28] followed by two 60-amino
acid imperfect repeats Repeat 1 (RPT1) and Repeat 2
(RPT2), and a C-terminal coil–coil domain (Fig. 1A).
RPT1 has been shown to be required for MYC interac-
tion [21,27]. The expression of residues 184–258 of
INI1, which encompasses RPT1, in Escherichia coli pro-
vided soluble protein that gave good quality 1H,15N
heteronuclear single quantum coherence (HSQC)
A
B C
D
Fig. 1. Structure of INI1/hSNF5 RPT1. (A)
Representation of the domain structure of
INI1. (B) Overlay of the 20 lowest energy
NMR structures of RPT1. (C) From left to
right: cartoon representations of the X-ray
structure of RPT1, and the structures of the
OSR1 CCT domain and the autoinhibitory
domain of WNK1 (WNK1-AI). (D) Schematic
of the topologies of the INI1/hSNF5 RPT1,
OSR1 CCT, and WNK1-AI domains.
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spectra with chemical shift dispersion typical of a well-
folded protein. INI1 RPT1 behaved as a monomer by
NMR and size exclusion chomatography–multi-angle
laser light scattering (SEC-MALS) analysis. Protein
samples were sufficiently stable to allow the collection
of the triple-resonance and nuclear Overhauser enhance-
ment spectroscopy data needed for chemical shift
assignment and solution structure determination
(Table 1). The NMR solution structure of this fragment
was determined (Fig. 1B) (PDB: 5L7B) and based on
this a shorter protein construct (184–252) was expressed
that readily crystallized. The crystal structure of this
protein was also determined using the NMR structure
as a molecular replacement model (Fig. 1C and see also
Table 2) (PDB: 5L7A). Residues 185–248 of INI1 form
a compact folded domain that contains two antiparallel
b-strands linked by a short loop followed by two a-
helices (Fig. 1D). The two strands form a curved base
onto which both helices pack and the structure is capped
at either end by loops that link the two strands, and
strand 2 and helix 1. This topology places the N- and C
termini of the domain in close proximity. The fold is sta-
bilized by a hydrophobic core that is primarily formed
by residues in b1 (I187, I189, L191, M193, I195) and a2
(F233, I237, I241, I245). In addition, the side chain of
Q244 in a2 forms hydrogen bonds to the backbone NH
and CO groups of R190 in b1, thereby linking the N-
and C termini of the domain. Comparison of the INI1
RPT1 structure to other known structures using the pro-
gram DALI [29] reveals significant similarities to domains
in two kinases involved in the regulation of osmotic
Table 1. Summary of conformational constraints and statistics for
the 20 accepted NMR structures of the human INI1/SNF5 RPT1
domain.
Structural constraints
Intraresidue 663
Sequential 393
Medium-range (2 < |i  j| < 4) 421
Long-range (|i  j| > 4) 539
Dihedral angle constraints 21
TALOS constraintsa 124
Distance constraints for 38 hydrogen bonds 76
Total 2237
Statistics for accepted structures
Statistical parameters (SD)
RMS deviation for distance constraints 0.0070  0.0004 A
RMS deviation for dihedral constraints 0.342  0.024°
Mean CNS energy term (kcalmol1  SD)
E (overall) 80.61  4.31
E (van der Waals) 19.87  1.35
E (distance constraints) 7.69  0.91
E (dihedral and TALOS constraints) 2.07  0.28
RMS deviations from the ideal geometry (SD)
Bond lengths 0.0015  0.0001 A
Bond angles 0.356  0.0078°
Improper angles 0.250  0.009°
Average atomic RMSD from the mean
structure (SD)
Residues 184–249 (backbone)b 0.237  0.053 A
Residues 184–249 (all heavy atoms)c 0.720  0.062 A
Structural qualityd
Residues in most favored region of
Ramachanran Plot
88.4%
Residues in additional allowed region
of Ramachandran Plot
10.4%
Residues in generously allowed region
of Ramachandran Plot
1.2%
Residues in disallowed region of
Ramachandran Plot
0.0%
PDB code 5L7B
a Dihedral angles are estimated using TALOS+-based chemical
shifts of backbone atoms of each amino acid. b Backbone heavy
atoms include backbone N, Ca, CO. c Heavy atoms include both
backbone and side chain non-hydrogen atoms. d Statistics are for
residues 184–259.
Table 2. Data collection and refinement statistics.
Native dataset
Data collection
Space group P21
Cell dimensions
a, b, c (A) 43.619, 73.653, 46.460
a, b, c (°) 90, 106.596, 90
Resolution (A)a 44.5–2.1 (2.22–2.10)
Total reflections 60 325
Unique reflections 15 711
Rsym or Rmerge (%)
b 0.060 (0.438)
I/rI 14.6 (3.3)
Completeness (%) 95.6 (93.3)
Redundancy 3.8 (3.9)
Refinement
Resolution (A) 45.0–2.1
No. reflections 15 656
Rwork/Rfree
c 20.0, 0.26.0
Number of atoms
Protein 2117
Water 130
B-factors
Protein 34.26
Water 35.40
RMS deviationsd
Bond lengths (A) 0.008
Bond angles (°) 0.918
PDB code 5L7A
a Highest resolution shell is shown in parenthesis. b Rm:∑h∑i|I/(h,
i)  I(h)|/∑h∑i/I(h, i) where I(h, i) are symmetry-related intensities
and I(h) is the mean intensity of the reflection with unique index h.
c R-factor = Σ(|Fobs|  k|Fcalc|)/Σ|Fobs| and R-free is the R value for a
test set of reflections consisting of a random 5% of the diffraction
data not used in refinement. dRMS deviations from ideal geometry
for bond lengths and restraint angles (Engh and Huber).
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stress, the CCT domain of oxidative stress responsive
kinase 1 (OSR1) [30] (Fig. 1C,D) and the autoinhibition
domain of lysine-deficient protein kinase 1 (WNK1) [31]
(Fig. 1C,D). Both domains share a core aabb motif
with INI1 RPT1 with additional elements of secondary
structure at the periphery of their folds (Fig. 1D). The
aabb motifs of the OSR1 and WNK1 domains can be
superimposed onto the structure of INI1 RPT1 with an
RMSD of 1.9 and 2.0 A, respectively.
The MYC:MAX bHLHZip dimer interacts with a
conserved site on INI1/hSNF5 RPT1
We next set out to identify which region of INI1 RPT1
interacts with MYC. The C-terminal part of MYC con-
taining the basic helix-loop-helix (bHLH) and leucine
zipper (Zip) domains has been shown to be required for
interaction with INI1 [21] and this interaction has been
reported to occur with MYC bound to its heterodimer-
ization-binding partner MAX [22]. We therefore coex-
pressed the bHLHZip region of MYC with the
corresponding region (bHLHZip) of MAX. We then
titrated purified unlabeled MYC:MAX bHLHZip
dimer into 15N-labeled INI1 RPT1. This produced sig-
nificant changes in the 1H,15N HSQC spectrum of INI1
RPT1 (Fig. 2C,D). The bound and free forms of the
domain are in fast exchange on the NMR timescale,
and analysis of the dependence of the changes in chemi-
cal shifts induced on the amount of MYC:MAX dimer
added gave a Kd of 44  6 lM for the interaction
(Fig. 3). The residues that undergo significant chemical
shift changes map to an elongated solvent-exposed
groove between b2 and a1 that has properties typical of
a PPI interface (Fig. 2B). Within this binding region,
there are a number of solvent-exposed hydrophobic
residues (F204, F218, I221, L226), which form two
shallow pockets. The binding interface also contains
two charged residues that undergo large changes in
chemical shift upon binding: D202, which is partially
buried, and D225, which is at the edge of the pocket
(Fig. 2). The second strand of the sheet (b2) runs along
the edge of binding interface. The backbone amides of
b2 (i.e., K199, R201, and A203) all undergo significant
changes in chemical shift. The resonance of N207 in the
loop between b2 and a1 at one end of the binding site
changes intensity rather than changing chemical shift
upon binding. This suggests that the interaction with
the MYC:MAX dimer may affect the dynamic proper-
ties of this region of the protein.
The domains structurally similar to RPT1 present in
the kinases OSR1 and WNK1 mediate PPIs involved
in substrate recognition and regulation. An X-ray
structure of the OSR1 CCT domain bound to a
peptide from a protein that regulates its activity has
been determined (PDB: 2V3S). The peptide binds in
an extended shallow pocket that is equivalent to the
binding site identified in INI1 RPT1 (Fig. 4). The
MYC:MAX dimer therefore appears to bind to a PPI
site common to this family of proteins.
The sequence of RPT1 is identical in species ranging
from humans to chicken (Fig. 5). The sequences of INI1
homologs in lower eukaryotes are more diverse, although
some residues are highly conserved. These include amino
acids that form the hydrophobic core as well as Q244,
which, as discussed above, also appears to contribute to
the stability of the fold. Many of the residues within the
binding sites are also highly conserved including the two
aspartates and several of the solvent-exposed hydropho-
bic residues. In contrast, solvent-exposed residues on the
face opposite to the binding groove are not conserved.
The role of residues in the binding site is difficult to
probe by mutagenesis as many of them are involved in
structurally important hydrogen bonding, or are
hydrophobic residues that also contribute to the stability
of the fold. We tested the effect of mutating two hydro-
philic residues within the binding site, D202 and N207 to
alanine. The integrity of the mutant proteins was
assessed by recording HSQC spectra. Only small changes
were observed for D202A mutant, however, much larger
changes were observed for the asparagine mutant sug-
gesting that its mutation alters the structure of the pro-
tein. The aspartate mutant showed reduced affinity to
the MYC:MAX dimer, such that it was not possible to
accurately determine a dissociation constant for its inter-
action, thus confirming that it forms part of the binding
site (Fig. 6). Repeats 1 and 2 present a high degree of
sequence similarity (Fig. 5). Many of the residues that
stabilize the fold in RPT1 are also conserved in RPT2,
which indicates that the structure of the two repeats is
very similar. Many of the residues within the binding site
identified in RPT1 are also conserved in RPT2, suggest-
ing that this region is functionally important in RPT2.
However, some of the amino acids conserved within the
binding site of RPT2 differ from RPT1, which is consis-
tent with data showing that the two repeats have differ-
ent binding specificities [32].
The INI1/hSNF5 RPT1 interacts with the helix-
loop-helix region of the MYC:MAX dimer
We next set out to use NMR to map the region of the
MYC:MAX dimer that interacts with INI1 RPT1.
Assignments for human MYC:MAX were not available
so we expressed 15N,13C-deuterated MYC:MAX
bHLHZip dimer and obtained backbone assignments
for it using triple resonance NMR experiments (BMRB
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accession number 27571). Complete assignments were
obtained for the leucine zipper (Zip), helix 2 (H2), the
loop region and the C-terminal part of helix 1 (H1) of
both MYC and MAX. As was observed for v-MYC
[33] the assignments for the N-terminal part of H1 in
both proteins could not be obtained potentially because
of exchange broadening due to fraying of this region.
The residues from the basic region of both MYC and
MAX are poorly dispersed (causing significant overlap
in the central region of spectra), which indicates that
they lack a stable structure in the absence of DNA,
hampering the full assignment of these regions.
The addition of the 1H,15N MYC:MAX bHLHZip
dimer to unlabeled INI1 RPT1 produced changes in the
chemical shifts of residues in both MYC and MAX
(Fig. 7A,C). Several peaks also undergo significant
change in intensity, either decreasing or increasing, to
the extent that some peaks are only visible in the bound
form, which suggests that binding is accompanied by
changes of the dynamic/conformational properties of
the heterodimer. The largest changes cluster on a dis-
crete patch on MYC, located at one end of the helix-
loop-helix (HLH) region (Fig. 7B,C), indicating that
this is the main binding site of INI1 RPT1 on the dimer
complex. The biggest change overall in chemical shift is
on MYC at the start of H2 (i.e., V393) (Fig. 7C).
Other significant changes in MYC are in the loop
that links H1 and H2, other residues at the N terminus
of H2, and residues in the basic region (Fig. 7B,C).
Some changes can be seen also in H1 (Fig. 7B,C):
A
B
C
Fig. 2. The MYC:MAX bHLHZip dimer binds to a conserved pocket on INI1/hSNF5 RPT1. (A) 1H,15N HSQC spectra of RPT1 without (black)
and with (magenta) the addition of unlabeled MYC:MAX bHLHZip dimer (ratio 1 : 2). Residues undergoing chemical shift changes more than
the standard deviation (SD) are labeled in black. (B) Cartoon (top) and molecular surface representation (bottom) of RPT1 showing the
residues that undergo chemical shift changes more than the standard deviation are highlighted in magenta and labeled. The chemical shift
changes of W206 are for the aromatic proton of the side chain (changes in chemical shifts of the backbone are below the threshold). (C)
Diagram showing the differences in chemical shifts induced by binding of the MYC:MAX dimer to the 15N-labeled INI1 RPT1. The black line
indicates the calculated standard deviation.
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Fig. 3. Kd determination of the binding of the MYC:MAX dimer to the INI1/hSNF5 RPT1. On the left overlay of 15N HSQC spectra showing
the variation of chemical shift changes induced on L222 by the addition of the unlabeled MYC:MAX dimer. The peak moves from right to
left with increasing concentration of the dimer; on the right, plot of the induced chemical shifts versus dimer concentration, fitted to a
single-site binding curve. INI1 RPT1 was employed at a concentration of 147 lM.
Fig. 4. Comparison of the binding site in INI1/hSNF5 RPT1 and OSR1. On the left cartoon representation of the structure of the OSR1 CCT
domain (green) in complex with the RFQV-peptide (yellow). On the right superimposition of the OSR1 CCT domain (not shown) complex
with the RFQV-peptide (yellow) with the RPT1 structure shown as a molecular surface, with the residues that change chemical shifts upon
binding to the MYC:MAX complex highlighted in magenta.
Fig. 5. Sequence alignments of the repeats of family members of the INI1/SNF5. At the top, carton representation of the secondary
structure elements of RPT1, followed by sequence alignments of RPT1 (middle) and RPT2 (bottom) for the Homo sapiens (Hs),
Drosophila melanogaster (Dm), Caenorhabditis elegans (Ce) and Saccharomyces cerevisiae (Sc) proteins.
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these changes are from residues that are close in space
to the residues affected in H2 and the Loop.
In MAX, the most significant changes in chemical
shift are for residues in H1 (Fig. 7B,C) that are across
the heterodimer interface from the affected residues on
MYC in H2 (Fig. 7B). There are also a few small
changes observed at the start of MAX H2. In both
proteins, H1 is only partially folded in the free dimer
and these changes may result from tightening of the
dimer upon forming the complex, rather than a direct
effect of the binding to INI1. The chemical shift map-
ping results are, therefore, consistent with MYC being
the main interaction partner of INI1 RPT1.
There are also changes in the basic region of MYC
(no changes are observed in the basic region of MAX).
Studies on the bHLH-transcription factors have shown
that binding to the HLH region can allosterically
induce conformational changes in the basic region [34].
Therefore, to understand if the changes in the basic
region of MYC are the results of direct binding we
then examined the interaction of INI1 with the MYC:
MAX HLHZip complex where both basic regions have
been removed. As the basic regions in the free MYC:
MAX complex are in a disordered conformation
removing them also helps with the analysis of the
NMR spectra (Fig. 8A). NMR data showed that
removing the basic regions does not compromise, or
alter the heterodimerization binding interface
(Fig. 8A), and biophysical analysis (i.e., DSC) of the
HLHZip complex also confirmed that the removal of
the basic regions does not destabilize the complex. On
the contrary, this complex seems to be more stable
having a melting point 7 °C higher than the construct
with the basic regions. The NMR spectra of the bind-
ing of 15N-labeled MYC:MAX HLHZip complex to
unlabeled INI1 RPT1 showed a comparable footprint
Fig. 6. Binding of the MYC:MAX dimer to the INI1 D202A-mutant. Overlay of a region of the 1H,15N HSQC spectra of RPT1 INI1 WT
without (blue gray) and with (green) unlabeled MYC:MAX bHLHZip dimer (ratio 1 : 1), overlaid with the overlay of the same region of the
1H,15N HSQC spectra of RPT1 INI1 D202A-mutant without (black) and with (red) unlabeled MYC:MAX bHLHZip dimer (ratio 1 : 1).
Highlighted in the red square is the residue L222 which undergoes the largest change in chemical shift upon binding of MYC:MAX complex
to both INI1 RPT1 WT and the D202A mutant. Comparison of the same ratio (1 : 1) illustrates the lower affinity of the DA mutant as the
change in chemical shift of L222 is significantly less.
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B
Fig. 7. INI1/hSNF5 RPT1 binds to the helix-loop-helix region of MYC in the MYC:MAX bHLHZip dimer. (A) 1H,15N BST TROSY spectra of
15N-labeled MYC:MAX bHLHZip dimer without (red) and with (black, ration 1 : 1) binding to RPT1 that move more than the standard
deviation are labeled. The region corresponding to residue V394 is inserted in the spectra in a box to better illustrate the changes of
chemical shifts that occur upon binding to INI1. (B) Cartoon representation of the MYC:MAX dimer (PDB = 1NKP, pink: MYC, gray: MAX)
with highlighted in red (MYC) and black (MAX) the residues labeled in the spectra. H1 = MYC Helix 1; H2 = MYC Helix 2. (C) Diagrams
showing the differences in chemical shifts induced by binding of RPT1 to the 15N-labeled MYC:MAX dimer (MYC on the left, MAX on the
right). Residues 29, 34–42, 52, 60, from MAX, and residues 366–71 from MYC are not assigned. L362 is assigned in the free form, but it
could not be assigned in the bound form. Residues 51, 382, 391 are prolines. The red line indicates the standard deviation. H1 = MYC Helix
1; H2 = MYC Helix 2.
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on the HLH region of MYC to that observed for
binding to the MYC:MAX bHLHZip (Fig. 8B,C).
Less chemical shift changes can be seen on MAX pos-
sibly (Fig. 8C), because as the structure is more stable,
there is less consolidation of heterodimer complex
upon binding of INI1. The binding affinity, however,
is significantly reduced to the point that is not possible
to determine a Kd. This suggests that the chemical shift
changes observed in the basic region are due to a
direct interaction.
The chemical shifts mapping results indicates that
INI1 docks onto one face of the heterodimer at one end
of the HLH motif of MYC (Fig. 7). This interaction
region on MYC does not appear to be an extended lin-
ear motif, in contrast to the interaction between the
OSR1 CCT domain and the RFQV-peptide.
INI1 RPT1 binding to MYC:MAX bHLHZip dimer is
incompatible with binding to E-box DNA
The MYC:MAX heterodimer binds to canonical E-box
DNA primarily via the basic regions with an affinity in
the nanomolar range [35]. INI1 RPT1 binds to a region
on MYC that is contiguous to the DNA binding motif,
and several of the residues in the putative interaction-
site in the HLH motif make contacts with the DNA in
the crystal structure of c-MYC:MAX bound to E-box
DNA (PDB: 1NKP). Furthermore, there is a strong
indication that residues in the basic region itself are
involved in the binding to INI1. We, therefore, tested if
INI1 RPT1 binding is compatible with the binding of
the MYC:MAX bHLHZip complex to canonical E-box
DNA. To this end, we first evaluated the binding of a
oligonucleotide containing a canonical E-box sequence
(the same E-box DNA sequence used in the reported
crystal structure) by adding 15N-labeled MYC:MAX
bHLHZip to the DNA. This produced large changes in
chemical shift and line broadening, confirming the for-
mation of the MYC:MAX bHLHZip/DNA complex
(MW = 34 kDa). An ITC analysis confirmed that the
binding is in the nano-molar range as previously
reported [35]. Then, we added 15N-labeled INI1 RPT1
to the unlabeled MYC:MAX bHLHZip/DNA complex.
No changes in chemical shifts, or line broadening, were
observed in the spectra of the 15N-labeled INI1 RPT1
(Fig 9: top panel). We also added the DNA to the pre-
formed MYC:MAX/15N-labeled INI1 RPT1 complex,
and observed displacement of the 15N-labeled INI1
RPT1 by the DNA, as observed by the recovery of a
spectrum corresponding to free 15N-labeled INI1 RPT1.
No changes in chemical shifts were also observed in the
spectra of 15N-labeled MYC:MAX complexed with E-
box DNA when unlabeled INI1 was added (Fig. 9: bot-
tom panel).
Discussion
Recently several studies have shown that loss of PPIs
that are mediated by INI1 is one of the major factors
contributing to oncogenesis in malignant rhabdoid
tumors [36,37]. Most of the PPIs made by this subunit
have been mapped to the repeats (1 and 2) [23], and
consistent with this the structure of RPT1 reveals a
fold that is an established PPI motif. We have shown
that MYC interacts with the canonical binding site of
this motif and, therefore, is likely to compete with
other binding partners of the SWI/SNF complex.
Interestingly, a recent paper has suggested that when
MYC is overexpressed it could compete with prodiffer-
entiation transcription factors for binding to the SWI/
SNF complex [38]. Furthermore, while this study was
being completed Yan et al. [39]. reported that the
MYC-binding groove of RPT1 interacts with the
BAF155 subunit of the SWI/SNF complex. This sug-
gests that MYC and other molecules binding to this
site could modulate the interactions between SWI/SNF
subunits, and alter the activity of the chromatin
remodeling complex.
The highly context dependent functionalities of the
SWI/SNF complex make it very difficult to use genetic
approaches to determine the role of the interaction
between MYC and the INI1. The use of chemical
probes [40] could instead be a more productive
approach because their effects are tunable, reversible,
and most relevant to this interaction, conditional as
they can be introduced at any point during cancer
development. The MYC binding region in INI1 RPT1
possesses features potentially amenable for small-mole-
cule binding, and an in silico assessment using LIG-
SITE [41], which is widely used to evaluate the
suitability of proteins to bind small molecules, pre-
dicted both the hydrophobic pockets within the MYC
binding region as potential small-molecule binding
sites (Fig. 10). Furthermore, targeting domains struc-
turally similar to the INI1 RPT1 has been successfully
carried out by fragment-based screening [42]. The bio-
physical data that we have obtained on INI1 RPT1
will allow the use of both structure-based design and
fragment-based approaches [43]. This strategy could
have a dramatic effect on the overall functionality of
the SWI/SNF complex, not just on the interaction
with MYC. This, though, could provide a means of
targeting the SWI/SNF complex itself for therapeutic
intervention [15].
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AC
B
Fig. 8. INI1/hSNF5 RPT1 binds to the helix-loop-helix region of MYC in the MYC:MAX dimer lacking the basic region. (A) 1H,15N BST
TROSY spectra of 15N-labeled MYC:MAX HLHZip dimer without (red) and with (black, ration 1 : 2) the addition of unlabeled RPT1
(residue 394 is inserted into the spectra as in Fig. 7). Residues implicated in the binding to RPT1 that move more than the standard
deviation are labeled. (B) Cartoon representation of the MYC:MAX dimer (pink: MYC, gray: MAX) with highlighted in red (MYC) and
black (MAX) the residues labeled in the spectra. H1 = MYC Helix 1; H2 = MYC Helix 2. (C) Diagrams showing the differences in
chemical shifts induced by binding of RPT1 to the 15N-labeled MYC:MAX dimer (MYC on the left, MAX on the right). Residues 39–42,
52, 370–71 are not assigned. Residues 51, 382, 391 are prolines. The red line indicates the standard deviation. H1 = MYC Helix 1;
H2 = MYC Helix 2.
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MYC is an intrinsically disordered protein where
the C-terminal only folds into a HLH-Zip structural
motif upon binding to the obligatory partner MAX
[44]. Because of their conformational flexibility, disor-
dered proteins such as MYC [45] typically make multi-
ple interactions with their partner proteins: this
multivalency allows them to mediate the formation of
stable and dynamic complexes [46]. MYC has been
reported to interact with multiple subunits of the SWI/
SNF chromatin remodeling complex [9], and may bind
to other regions of INI1 (i.e., RPT2) [22], although
these interactions have not been characterized. This
suggests that MYC makes multivalent interactions
with the SWI/SNF complex. The Kd value of the
MYC:INI1 RPT1 interaction fits well with a multiva-
lent mode of interaction in which individual
components have a relatively modest affinity, but high
specificity. In this context, it is relevant to highlight
that the only other well-characterized MYC interaction
[47] with a component of chromatin regulatory com-
plexes (i.e., WDR5) has a similar Kd value to the one
for the MYC:INI1 interaction herein reported. A mul-
tivalent mode of binding may allow additional levels
of regulation (e.g., post-translational modification) to
play a role in directing what type of SWI/SNF:MYC
interaction takes place on target genes. Interestingly,
the binding regions identified in both MYC and INI1
RPT1 are subjected to post-translational modifications,
such as phosphorylation, acetylation, and ubiquitina-
tion [48].
One striking feature of the binding of INI1 on the
MYC is its interplay with the binding of the MYC:
Fig. 9. Binding of INI1/hSNF5 RPT1 and
DNA to the MYC:MAX bHLHZip dimer are
mutually exclusive. Top: overlay of 1H,15N
HSQC spectra of RPT1 without (black) and
with (red, ratio 1 : 1) unlabeled MYC:MAX
bHLHZip dimer bound to DNA. Bottom:
overlay 1H,15N BST TROSY spectra of 15N-
labeled MYC:MAX bHLHZip dimer bound to
DNA without (black) and with (red, ratio
1 : 1) unlabeled RPT1 INI1. In both spectra,
no chemical shift changes are observed,
illustrating that INI1 RPT1 does not bind to
the MYC:MAX dimer when this is bound to
E-box DNA.
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MAX dimer to DNA. The interaction maps to a large
region involving the HLH motif and the beginning of
the basic region. This shows that this region is not
only involved in dimerization and DNA binding, but
it is also important in mediating PPIs. In fact, our
study shows for the first time that the interaction of
MYC with a cofactor competes with the MYC:MAX
dimer binding to DNA. In particular, we have found
that binding of INI1 and DNA to the MYC:MAX
complex are mutually exclusive: the interaction of
INI1 RPT1 with the MYC:MAX dimer does not take
place when MYC is bound to E-box DNA, which is at
first hand an unexpected result as conventionally one
would expect that a transcription factor would recruit
the SWI/SNF complex to its cognate DNA. This has
potentially important functional implications. The fac-
tors governing the distribution of MYC on the genome
are known to be diverse, and to include[49,50]: direct
interactions with DNA containing both high-affinity
canonical E-box sequences and other lower affinity
sites, as well as multiple low-affinity PPIs between the
MYC:MAX dimer and other chromatin-associated
protein complexes, and/or transcription factors, such
as MIZ1 [51], which themselves can bind to DNA. Site
distribution has been suggested to depend on the level
of MYC in the cell, with lower affinity sites being
occupied in tumors with high levels of MYC expres-
sion. At sites where MYC:MAX does not directly bind
to DNA, the MYC:MAX complex will be available to
interact with INI1. At other sites the binding of INI1
to MYC:MAX would compete with DNA with the
outcome depending on the relative affinities. As men-
tioned above, it is possible that MYC makes other
contacts with the SWI/SNF complex; the avidity effect
of this multivalent mode of binding would then result
in a higher affinity interaction, thus enabling the SWI/
SNF complex to displace MYC from DNA – espe-
cially at lower affinity sites [50]. This could explain the
observations that the SWI/SNF complex can decrease
MYC’s binding to some of its target genes in lung can-
cer cell lines; and that when INI1 is introduced into
INI1-deficient rhabdoid tumor cells, MYC binding is
reduced at some of its target genes [22]. Our findings
about the competition with DNA binding would be,
therefore, consistent with INI1 negatively regulating
MYC transcriptional activity.
Overall, this work highlights how MYC operates via
a complex network of competing interactions, and
offers a potential means to manipulate its functions.
Materials and methods
Material
Chemicals were acquired from Sigma-Aldrich (St. Louis,
MO, USA) or Fisher Scientific (Fremont, CA, USA) and
were used without further purification. Ni-NTA resin was
from Qiagen (Manchester, UK), Amicon centrifugal units
were obtained from Millipore (Billerica, MA, USA). PCR
primers were obtained from IDT (Integrated DNA Tech-
nologies, Leuven, Belgium).
DNA cloning, and protein expression and
purification
INI1/hSNF5
The DNA encoding the residues 184–258 of INI1 was
amplified from human cDNA by PCR and cloned into a
modified pRSETA (Invitrogen, Life Sciences, Paisley, UK)
expression vector that produces proteins fused to N-terminally
His6-tagged lipoyl domain of Bacillus stearothermophilus
dihydrolipoamide acetyltransferase. The resulting plasmids
were transformed into E. coli C41 (DE3) cells. Cells were
grown in 2XTY media at 37 °C to mid-log phase and
induced with 1 mM IPTG. The temperature was reduced to
22 °C, and the cells were grown for a further 16 h. Iso-
topically labeled domains were prepared by growing cells
in K-MOPS minimal media containing 15NH4Cl and/or
[13C]-glucose. Cells where lysed by sonication, and the
fusion protein was purified by Ni2+-NTA affinity chro-
matography. The purified protein was dialyzed overnight
in the presence of TEV protease, which cleaves the fusion
protein after the lipoyl domain. A second Ni2+-NTA affin-
ity chromatography step was carried out to remove the
Fig. 10. Potential small-molecule binding pockets in INI1/hSNF5
RPT1. Molecular surface representation of INI1/hSNF5 RPT1
showing the residues that undergo chemical shift more than
standard deviation highlighted in magenta, and in green spheres
representing three potential small-molecule binding pockets that
were identified by the LIGSITE program.
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lipoyl domain and the protein was further purified by gel
filtration using a HiLoad 26/60 Superdex 75 column (GE
Healthcare, Little Chalfont, UK).
c-MYC:MAX bHLHZip (MYC = 352–437,
MAX = 22–102) and c-MYC:MAX HLHZip
(MYC = 368–437, MAX = 36–102)
Soluble His6 MYC:MAX bHLHZip, or His6 MYC:MAX
HLHzip heterodimer, was produced in E. coli using a
pET28a derived plasmid that directs the coexpression of both
proteins from a polycistronic mRNA, using a similar
approach to Fieber et al. [52]. Chemically competent E. coli
BL21 (DE3) cells were transformed with this plasmid. Cells
were plated on Luria-Bertani agar supplemented with kana-
mycin. A single colony was used to inoculate a culture of
either 2XTY broth or K-MOPS minimal media prepared in
D2O containing
15NH4Cl and [
13C]-glucose. Cell were grown
at 22 °C to an OD 600 of 0.8 and then induced with 1 mM
IPTG. Cells were grown for a further 16 h before being col-
lected by centrifugation. Cells were lysed by sonication. For
the MYC:MAX bHLHZip complex, this is followed by the
addition of DNAse I (150 lL for 1 g of culture pellet) and
incubation for 1 h at 37 °C (90 r.p.m.). Centrifugation at
38 000 g at 4 °C for 45 min is then carried out.
The dimer was purified at 25 °C by affinity chromatogra-
phy using a HisTRAP column (GE Healthcare) according
to the standard protocol for Ni2+-NTA affinity chromatog-
raphy recommended by the manufacturer, and dialyzed
against PBS (with 1–10 mM DTT) overnight at 5 °C. Ali-
quots of the protein complex were snap-frozen in liquid
nitrogen and stored at 80 °C.
NMR
INI1/hSNF5 samples prepared for NMR spectroscopy
experiments were typically 1.5 mM for structural determina-
tion in 90% H2O, 10% D2O, containing 20 mM potassium
phosphate, pH 6.5, 100 mM NaCl, and 5 mM b-mercap-
toethanol. All spectra were acquired using a Bruker
DRX800, DRX600, or DMX500 spectrometer equipped
with pulsed field gradient triple resonance at 25 °C, and
referenced relative to external sodium 2,2-dimethyl-2-sila-
pentane-5-sulfonate for proton and carbon signals, or liq-
uid ammonia for that of nitrogen. Assignments were
obtained using standard NMR methods using 13C,15N-
labeled, 15N-labeled, 10%13C-labeled, and unlabeled pro-
tein samples [53]. Backbone assignments were obtained
using the following standard set of 2D and 3D heteronu-
clear spectra: 1H-15N HSQC, HNCACB, CBCA(CO)NH,
HNCACO, HNCO, HBHA(CO)NH, and 1H-13C HSQC.
Additional assignments were made using 2D TOCSY and
DQF-COSY spectra. A set of distance constraints were
derived from 2D NOESY spectra recorded from a 1.5 mM
sample with a mixing time of 120 ms. Hydrogen bond
constraints were included for a number of backbone amide
protons whose signals were still detected after 10 min in a
2D 1H-15N-HSQC spectrum recorded in D2O at 278 K (pH
5.0). Candidates for the acceptors were identified using the
program HBPLUS for the hydrogen bond donors that were
identified by the H–D exchange experiments. When two or
more candidates of acceptors were found for the same
donor in different structures, the most frequently occurring
candidate was selected. For hydrogen bond partners, two
distance constraints were used where the distance (D)H–
O(A) corresponded to 1.5–2.5 A and (D)N–O(A) to 2.5–
3.5 A. Torsional angle constraints were obtained from an
analysis of C’, N, Ca Ha and Cb chemical shifts using the
program TALOS [54]. The stereospecific assignments of Hb
resonances determined from DQF-COSY and HNHB spec-
tra were confirmed by analyzing the initial ensemble of
structures. Stereospecific assignments of Hc and Hd reso-
nances of Val and Leu residues, respectively, were assigned
using a fractionally 13C-labeled protein sample [55]. The
three-dimensional structure of the INI1 domain (residues
183–258) was calculated using the standard torsion angle
dynamics-simulated annealing protocol in the program CNS
1.2 [56]. Structures were accepted where no distance viola-
tion was greater than 0.25 A and no dihedral angle viola-
tions > 5°. The final coordinates have been deposited in the
Protein Data Bank (PDB accession no. 57LB).
Labeled MYC:MAX samples prepared for NMR spec-
troscopy experiments were typically 200–300 lM in PBS,
10% D2O, pH 7, and 1 mM DTT. All spectra were acquired
using a Bruker DRX800 (Bruker BioSpin, Billerica, MA,
USA) (binding experiments) or DRX950 (for NMR assign-
ments) spectrometers equipped with pulsed field gradient tri-
ple resonance cryoprobe at 25 °C. Backbone assignments
were carried using the following standard set of 3D heteronu-
clear spectra on deuterated samples: HNCO, HN(CA)CO,
HNCACB, CBCA(CO)HN. The assignments have been
deposited in the Biological Magnetic Resonance Bank
(BMRB, accession number 27571).
Chemical shift perturbations were calculated using the
root mean square deviation of the changes of the H and N
chemical shifts, using a correction factor for the N chemical
shifts as discussed by Williamson [57].
Crystallography
Crystals of INI1/hSNF5 (concentration of 6 mgmL1)
were grown using the vapor diffusion method at 4 °C using
a precipitant of 1.4 M tri-sodium citrate and 100 mM
HEPES pH 7.5. Crystals were immersed into the precipi-
tant solution supplemented with 20% (v/v) glycerol prior
to vitrification by direct immersion into liquid nitrogen.
Native data was collected in-house on an Fr-E Superbright
rotating anode generator (Rigaku Corp, Tokyo, Japan),
equipped with a MarDTB image plate detector (mar-
research GmbH, Norderstedt, Germany). Diffraction data
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were indexed and integrated with XDS [58] and scaled and
merged with SCALA [59]. The crystal structure of the trun-
cated construct (183–252) of human INI1 was solved by
molecular replacement using the NMR structure as a
search model. Density modification produced experimental
maps that allowed for manually refinement using MAIN and
COOT [60]. The crystal structure was refined to 2.1 A using
PHENIX [61] and is consistent with the NMR structure
(RMSD of 0.77 A for the backbone atoms of residues 185–
245). The crystallographic data are summarized in Table 2.
The validity of all models was routinely determined using
MOLPROBITY (http://molprobity.biochem.duke.edu/) and by
using the free R factor to monitor improvements during
building and crystallographic refinement. The final coordi-
nates have been deposited in the Protein Data Bank (PDB
accession no. 57LA).
Accession numbers
NMR structure of INI1/hSNF5 RPT1- PDB ID:
5L7B. Crystal structure of INI1/hSNF5 RPT1- PDB
ID: 5L7A. NMR assignments of c-MYC:MAX
bHLHZip complex – BMRB accession number 27571.
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